Literature DB >> 34222443

Pheochromocytoma with abdominal aortic aneurysm presenting as recurrent dyspnea, hemoptysis, and hypotension: A case report.

Hai-Yang Zhao1, Yong-Zhen Zhao1, Yu-Mei Jia2, Xue Mei1, Shu-Bin Guo3.   

Abstract

BACKGROUND: Pheochromocytomas are rare endocrine tumors with various clinical manifestations, and few of them might present with profound, life-threatening conditions. CASE
SUMMARY: We report the case of a 65-year-old man who complained of sudden dyspnea and hemoptysis for half a day. There was no obvious cause for the patient to have dyspnea, coughing, or coughing up to approximately 100 mL of fresh blood. Finally, he was diagnosed with pheochromocytoma crisis (PCC), coexisting with an abdominal aortic aneurysm (AAA).
CONCLUSION: We report a case of pheochromocytoma presenting with recurrent hemoptysis, dyspnea and hypotension coexisting with an AAA. It not only proved the uncommon manifestations of pheochromocytoma but also directed clinicians to consider PCC among the possible diagnoses when meeting similar cases. Moreover, surgical excision is the most beneficial method for the treatment of pheochromocytoma coexisting with AAA when the situation is stable. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm; Case report; Emergency; Hemoptysis; Hypotension; Pheochromocytoma crisis

Year:  2021        PMID: 34222443      PMCID: PMC8223855          DOI: 10.12998/wjcc.v9.i18.4754

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


Core Tip: We report a case of pheochromocytoma presenting with recurrent hemoptysis, dyspnea, and hypotension coexisting with an abdominal aortic aneurysm. It not only proved the uncommon manifestations of pheochromocytoma but also directed clinicians to consider pheochromocytoma crisis among the possible diagnoses when meeting similar cases.

INTRODUCTION

Pheochromocytomas are rare endocrine tumors with various clinical manifestations, and a small number of them might present with profound, life-threatening conditions. We report a case of pheochromocytoma presenting with recurrent hemoptysis, dyspnea, and hypotension, coexisting with an abdominal aortic aneurysm, and with a positive outcome. We discuss the management and treatment of the patient in this case report and the proposed mechanisms.

CASE PRESENTATION

Chief complaints

A 65-year-old man was taken to our emergency department, complaining of sudden dyspnea and hemoptysis for half a day. There was no obvious cause for the patient to have dyspnea, coughing, or coughing up to approximately 100 mL of fresh blood.

History of present illness

The patient had four episodes of similar symptoms in the past 10 years. The first three episodes had dyspnea accompanied by hypertension, without hemoptysis, and only the symptoms were treated; the cause had not been identified. Dyspnea, hemoptysis, and hypotension occurred 5 years ago. He was hospitalized at our hospital, and a left adrenal mass and an abdominal aortic aneurysm (AAA) were found. An abdominal computed tomography (CT) scan showed a left adrenal mass measuring 3.2 cm × 3.6 cm and an AAA with a maximum diameter of 5.3 cm. Surgical treatment was not performed because the patient worried about the risks of surgery.

History of past illness

The patient was healthy.

Personal and family history

The patient had a disease-free personal and family history.

Physical examination

On physical examination, the patient was dyspneic, in distress, and sweating profusely. His blood pressure was 87/50 mmHg, heart rate was 107 beats/min, respiratory rate was 35 breaths/min, body temperature was 36 °C, and oxyhemoglobin saturation was 88% while breathing a 50% oxygen concentration with a face mask.

Laboratory examinations

Initial laboratory tests demonstrated leukocytosis (25.73 × 109/L, with 93.6% neutrophils) and significantly increased serum procalcitonin at 58.4 ng/mL (normal value: < 0.05 ng/mL). Blood gas analysis revealed lactate 11.0 mmol/L, pH 7.31, PaO2 72.1 mmHg, PaCO2 32.3 mmHg, and HCO3– 18.9 mmol/L while breathing 100% oxygen concentration with noninvasive positive pressure ventilation (NIPPV). His liver and renal function was also abnormal (alanine transaminase 145 U/L, glutamic-oxaloacetic transaminase 156 U/L, and creatinine 126 µmol/L), and D-dimer was 28.85 mg/L (normal value: ≤ 0.55 mg/L). Electrocardiogram showed sinus tachycardia and ST segment depression in the V2-V6 leads.

Imaging examinations

The patient’s chest X-ray manifestations were characterized by multiple plaques in both lungs, chest CT scans showed little ground glass shadow under the pleura of both lungs (Figure 1), and abdominal CT scans showed a left adrenal mass measuring 4.4 cm × 4.3 cm and an AAA with a maximum diameter of 7.3 cm (Figure 2). Echocardiography showed enlargement of the left atrium, aortic sinus, and ascending aorta. Systolic left ventricular function was impaired (ejection fraction 55%), but there was no pulmonary hypertension and no sign of diastolic dysfunction (left ventricular end diastolic diameter 55 mm).
Figure 1

Chest computed tomography scans showing little ground glass shadow under the pleura of both lungs.

Figure 2

Enhanced computed tomography images. A: Enhanced computed tomography (CT) of the abdomen showing a round-like mass (4.4 cm × 4.3 cm) (orange arrowhead); B: Enhanced CT of the abdomen depicting a 7.0 cm × 7.3 cm abdominal aortic aneurysm (orange arrowhead).

Chest computed tomography scans showing little ground glass shadow under the pleura of both lungs. Enhanced computed tomography images. A: Enhanced computed tomography (CT) of the abdomen showing a round-like mass (4.4 cm × 4.3 cm) (orange arrowhead); B: Enhanced CT of the abdomen depicting a 7.0 cm × 7.3 cm abdominal aortic aneurysm (orange arrowhead).

FINAL DIAGNOSIS

The final diagnosis of the present case was pheochromocytoma crisis (PCC) and abdominal aortic aneurysm.

TREATMENT

Although PCC was considered, septic shock cannot be excluded. After treatment with antibiotic (imipenem), fluid resuscitation, and NIPPV for relieving dyspnea, the patient’s condition improved on the second day, except for blood pressure. Dopamine (5-10 μg/kg/min) was used to support blood pressure. On the third day, the patient completely stopped hemoptysis and the leukocyte count recovered to normal. Considering that there was no evidence of infection and no fever, which did not fit with the diagnosis of sepsis, step-down treatment was adopted for anti-infection. Tests of plasma and urine catecholamines and metabolites were performed. The levels of dopamine and methoxyepinephrines were increased in both the urine and 24-h urine. To our surprise, the level of plasma adrenocorticotropic hormone (ACTH) was decreased (Table 1). In addition, the blood cortisol level was slightly reduced. Magnetic resonance imaging of the pituitary gland was normal. The levels of angiotensin II, aldosterone, and renin were normal. One week later, the patient had no obvious discomfort, and blood pressure returned to normal. He was discharged. The repeated tests were performed 7 d after discharge (Table 1). Persuaded by us and his family, the patient finally made up his mind to undergo operation. The abdominal aortic aneurysm was repaired first by endovascular exclusion of abdominal aortic aneurysm, and 1 mo later, he underwent laparoscopic left adrenal tumor resection. Pathological examination confirmed the diagnosis of left adrenal pheochromocytoma.
Table 1

The patient’s catecholamine, methoxyepinephrines, and adrenocorticotropic hormone levels

Laboratory test
On admission
Seven days out of hospital
Normal range
Serum catecholamine
AD (pg/mL)31.7747.950.00-100.00
NA (pg/mL)141.48600.530.00-600.00
DOP (pg/mL)243.5552.090.00-100.00
Serum methoxyepinephrines
3-MT (nmol/L)55.89< 0.08< 0.18
NMN (nmol/L)0.660.71≤ 0.50
MN (nmol/L)1.953.64≤ 0.90
24-h urinary catecholamine
24 h AD(μg/d)11.658.380.00-20.00
24 h NA (μg/d)24.5548.340.00-90.00
24h DOP (μg/d)1448.7153.570.00-600.00
24-h urinary methoxyepinephrines
24 h 3-MT (nmol/d)14443266< 216
24 h NMN (nmol/d)579682< 216
24 h MN (nmol/d)276169< 382
ACTH (pg/mL)5.026.07.2-63.3

AD: Adrenaline; NA: Noradrenaline; DOP: Dopamine; 3MT: 3-methoxytyramine; NMN: Normetanephrin; MN: Metanephrine; ACTH: Adrenocorticotropic hormone.

The patient’s catecholamine, methoxyepinephrines, and adrenocorticotropic hormone levels AD: Adrenaline; NA: Noradrenaline; DOP: Dopamine; 3MT: 3-methoxytyramine; NMN: Normetanephrin; MN: Metanephrine; ACTH: Adrenocorticotropic hormone.

OUTCOME AND FOLLOW-UP

The patient was followed for 5 mo and showed no signs of recurrence.

DISCUSSION

Pheochromocytomas are catecholamine-secreting tumors arising from chromaffin cells of the adrenal medulla and the sympathetic ganglia. The typical clinical presentation consists of episodic headache, diaphoresis, and tachycardia accompanied by paroxysmal or essential hypertension[1]. However, PCC has dramatic and fulminant clinical expression and is usually associated with significant mortality. PCC as an endocrine emergency has been defined as the acute severe presentation of catecholamine-induced hemodynamic instability causing end-organ damage or dysfunction, usually associated with significant mortality[2]. However, due to catecholamine overrelease, PCC can mimic other common conditions and thus frequently is initially misdiagnosed[3]. As the clinical manifestations of the present case were featured by hypotension, hemoptysis, dyspnea, and multiple organ dysfunction syndrome on admission, we may easily miss the diagnosis of pheochromocytoma. Many patients choose surgery after the first attack of PCC. In this case, the patient did not undergo surgery; therefore, he had recurrent PCC. The patient’s medical history contributed to our diagnosis. However, hemoptysis, dyspnea, and hypotension were nonspecific signs. Bedside echocardiography helped us rule out heart disease and pulmonary embolism. Due to the widespread actions of catecholamines, pheochromocytomas may present with numerous conditions or diseases. Massive hemoptysis can be the main manifestation[4,5]. Pulmonary venous hypertension secondary to severe paroxysmal hypertension was thought to be a possible cause of hemoptysis[4]. In addition, Kimura et al[6] reported that increased activation of the coagulation cascade and endothelial or platelet stimulation, evidenced by increased plasma von Willebrand factor, may have contributed to hemoptysis. The patient had recurrent PCC five times; the first three had hypertension, but the next two had sustained hypotension. Whitelaw et al[7] suggest that a PCC without sustained hypotension is classified as a type A crisis, whereas a severe presentation with sustained hypotension, shock, and multiorgan dysfunction is classified as a type B crisis. However, the pathological processes of hypotension are not well understood. Norepinephrine and epinephrine are hypothesized to be the primary causes of tumor-induced alterations in hypotension. The primary mechanism seems to be excess plasma epinephrine stimulating β2 receptors to cause vasodilation[8], and norepinephrine is thought to be related to myocardial dysfunction, hypovolemia, and desensitization of baroreflexes[9,10]. In addition, ACTH secretion should increase under stress, but the ACTH and cortisol levels in this case were relatively reduced. We suspect that the reason may be related to ischemia-reperfusion after the severe contraction of pituitary blood vessels caused by pheochromocytoma hormone storm. Such insufficient stress may also be one of the reasons for hypotension. Many reports describe the use of various inotropes and vasopressors (including adrenaline, noradrenaline, dopamine, dobutamine, vasopressin, and levosimendan) to manage sustained hypotension and circulatory compromise[11-13]. We used dopamine for a week. The results of related tests might be affected by the use of this drug. It is unclear if any of these provide significant benefit in the circumstances, but the literature more generally supports the use of vasopressin[14]. The coexistence of pheochromocytoma and AAA poses certain problems, and surgical intervention in these patients carries a significant risk of myocardial infarction, cerebrovascular accident, and cardiovascular collapse. In the preoperative period, there is an increased risk of rupture of the aneurysm, caused by excess catecholamine and hypertension[15]. Also, resecting the pheochromocytoma places the aneurysm at an increased risk of rupture in the postoperative period. Taking these factors into consideration, our patient was subjected to endovascular exclusion of abdominal aortic aneurysm first, and 1 mo later, the patient underwent laparoscopic left adrenal tumor resection. Further studies are needed to determine whether it is possible to repair adrenal tumors and aneurysms at the same time, and the intraoperative management will be a challenging issue.

CONCLUSION

We report a case of pheochromocytoma presenting with recurrent hemoptysis, dyspnea, and hypotension coexisting with an abdominal aortic aneurysm. It not only proved the uncommon manifestations of pheochromocytoma but also directed clinicians to consider PCC among the possible diagnoses when meeting similar cases. Moreover, surgical excision is the most beneficial method for the treatment of pheochromocytoma coexisting with AAA when the situation is stable.
  15 in total

1.  A pheochromocytoma causing limited coagulopathy with hemoptysis.

Authors:  Yoko Kimura; Hideki Ozawa; Mihoko Igarashi; Tomooki Iwamoto; Kenzo Nishiya; Tetsuya Urano; Shinya Goto
Journal:  Tokai J Exp Clin Med       Date:  2005-04

2.  Pheochromocytoma presenting as recurrent hypotension and syncope.

Authors:  Tamenobu Ueda; Naoki Oka; Akira Matsumoto; Hiroshi Miyazaki; Haruya Ohmura; Toshio Kikuchi; Moto Nakayama; Seiya Kato; Tsutomu Imaizumi
Journal:  Intern Med       Date:  2005-03       Impact factor: 1.271

3.  Multidisciplinary management of giant functional petrous bone paraganglioma.

Authors:  Thomas Graillon; Stéphane Fuentes; Jean Régis; Philippe Metellus; Hervé Brunel; Pierre-Hughes Roche; Henry Dufour
Journal:  Acta Neurochir (Wien)       Date:  2010-10-08       Impact factor: 2.216

4.  Pheochromocytoma presenting as massive hemoptysis and acute respiratory failure.

Authors:  Takeshi Yoshida; Hideki Ishihara
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

5.  Phaeochromocytoma [corrected] crisis.

Authors:  B C Whitelaw; J K Prague; O G Mustafa; K-M Schulte; P A Hopkins; J A Gilbert; A M McGregor; S J B Aylwin
Journal:  Clin Endocrinol (Oxf)       Date:  2013-10-17       Impact factor: 3.478

6.  Vasopressin versus norepinephrine infusion in patients with septic shock.

Authors:  James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

7.  Phaeochromocytoma crisis--a rare indication for extracorporeal membrane oxygenation.

Authors:  A Chao; Y C Yeh; T S Yen; Y S Chen
Journal:  Anaesthesia       Date:  2008-01       Impact factor: 6.955

Review 8.  Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment.

Authors:  Elizabeth A Mittendorf; Douglas B Evans; Jeffrey E Lee; Nancy D Perrier
Journal:  Hematol Oncol Clin North Am       Date:  2007-06       Impact factor: 3.722

9.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

Authors:  Martin Fassnacht; Wiebke Arlt; Irina Bancos; Henning Dralle; John Newell-Price; Anju Sahdev; Antoine Tabarin; Massimo Terzolo; Stylianos Tsagarakis; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2016-08       Impact factor: 6.664

10.  Pheochromocytoma mimicking both acute coronary syndrome and sepsis: a case report.

Authors:  Ting-Wei Lee; Ke-Hsun Lin; Chun-Jen Chang; Wei-Han Lew; Ting-I Lee
Journal:  Med Princ Pract       Date:  2012-10-27       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.